CBD-Augmentation zeigte keine Verbesserung kognitiver oder psychotischer Symptome gegenüber Placebo bei chronischer Schizophrenie.
Zusammenfassung
n=36 stabile antipsychotisch behandelte Patienten mit chronischer Schizophrenie; 6-wöchiges CBD 600 mg/d vs. Placebo als Augmentation. Kein Haupteffekt auf MCCB-Gesamtscore; signifikanter Medikament×Zeit-Effekt (p=0,02), jedoch nur Placebo-Gruppe verbesserte sich (p=0,03). PANSS-Total nahm über die Zeit ab (p<0,0001), kein signifikanter Unterschied zwischen den Gruppen (p=0,18). Negatives RCT — CBD-Augmentation verbesserte Kognition oder Symptome nicht.
P
PopulationAmbulante Patienten mit chronischer Schizophrenie unter stabiler Antipsychotika-Behandlung, n=36
I
InterventionOrales CBD 600 mg/Tag, 6 Wochen, als Augmentation zur bestehenden Antipsychotika-Therapie
C
KontrollePlacebo (oral, als Augmentation)
O
OutcomeKein signifikanter Haupteffekt von CBD auf den MCCB-Gesamtscore; signifikante Drug×Zeit-Interaktion (p=0,02), wobei nur die Placebo-Gruppe eine Verbesserung über die Zeit zeigte (p=0,03); kein signifikanter Drug×Zeit-Effekt auf PANSS-Gesamtscore (p=0,18)
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
<h4>Rationale</h4>Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS).<h4>Objective</h4>This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial.<h4>Methods</h4>This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly.<h4>Results</h4>There was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug × time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group.<h4>Conclusions</h4>At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.<h4>Trial registration</h4>https://clinicaltrials.gov/ct2/show/NCT00588731.